MHRA approves clinical trial of investigational angiotensin II receptor type 2 agonist (VP01) for SARS CoV- 2 infection

The Phase II ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) study will investigate use of VP01 in the treatment of hospitalised patients treated with basic respiratory care, but not mechanical ventilation. The MHRA approved the study in record time.